Search Results for: HCV

November 10, 2014November 11, 2014

New Combination Therapy Works Well With Liver Transplants In Hepatitis C

Hepatitis C, News

During the American Association for the Study of Liver Diseases (The Liver Meeting® 2014) to be held in Boston, MA, between November 7 and 11, a new report will be ... Read more

November 6, 2014November 6, 2014

Genotype 1 Chronic Hepatitis C Infection Drug OLYSIO Granted Additional FDA Approval

Hepatitis C, News

The U.S. Food and Drug Administration (FDA) has approved the combination therapy of OLYSIO® (simeprevir), developed by Janssen R&D Ireland and Medivir AB, with sofosbuvir as an alternative treatment for ... Read more

November 5, 2014November 5, 2014

Theravance Biopharma Announces Positive Results From NS5A Inhibitor Hepatitis C Drug Phase 1 Proof-of-Concept Study

Hepatitis C, News

Theravance Biopharma, through its U.S. operating subsidiary, South San Francisco, California-based Theravance Biopharma US, Inc., on Tuesday announced positive results from the first three cohorts of Study 0110 — a ... Read more

November 4, 2014November 4, 2014

U.K. Hepatitis C Services “Unacceptable” — Contribute To “Thousands Of Unnecessary Deaths”

Hepatitis C, News

According to the U.K. Hepatitis C Coalition, half of people living with hepatitis C are still undiagnosed, and just 3% of those infected are treated each year — a state of ... Read more

November 3, 2014November 3, 2014

Swedish County Councils Signs Agreement for Hepatitis C Therapy Olysio

Hepatitis C, News

The Swedish county councils has established a risk-sharing agreement with research-based pharmaceutical company Medivir AB for the medication Olysio (simeprevir) for hepatitis C, including its treatment costs, as a way of making ... Read more

October 30, 2014October 30, 2014

Australia Declines to Subsidize Hepatitis C Drug Therapy Sofosbuvir

Hepatitis C, News

The drug Sofosbuvir, for the treatment of hepatitis C, produced by Gilead Sciences, will not be subsidized by the Australian government, due to its costs. The Pharmaceutical Benefits Advisory Committee (PBAC) announced that ... Read more

October 23, 2014October 23, 2014

New Chronic Hepatitis C, Genotype 1 Infection Drug Approved By FDA

Hepatitis C, News

Approval for a new chronic hepatitis C (HCV) treatment, genotype 1 infection in adults, was recently announced by the U.S. Food and Drug Administration (FDA). The drug — Harvoni® (ledipasvir/sofosbuvir) — is manufactured ... Read more

October 22, 2014October 22, 2014

Enanta Foregoes Co-development Option For Hep C Drug With AbbVie

Hepatitis C, News

Enanta Pharmaceuticals, Inc. has just announced it will forego its co-development option with AbbVie for their next-generation protease inhibitor, ABT-493, indicated for the treatment of hepatitis C. The CDC estimates that ... Read more

October 21, 2014October 22, 2014

Sovaldi Better for Cost Issues in Hep C Treatments for Inmates

Hepatitis C, News

The treatment of inmates remains a hot-button issue that includes a wide range of different considerations, ranging from how well cared-for a prisoner should be to the economics involved in maintaining ... Read more

October 20, 2014October 20, 2014

New Oral Drugs Show Promise as Hepatitis C Cure

Hepatitis C, News

A pair of highly promising drug study results are scheduled to be presented during the 22nd United European Gastroenterology Week (UEG Week 2014), which began in Vienna, Austria on Saturday, October 18. The conference will ... Read more